Showing 18,861 - 18,880 results of 30,491 for search '(( 50 ((nn decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 2 step decrease ))', query time: 1.01s Refine Results
  1. 18861
  2. 18862

    Characteristics of Physician Outflow from Disaster Areas following the Great East Japan Earthquake by Saori Kashima (126020)

    Published 2017
    “…<div><p>Objective</p><p>The shortage of physicians after a major disaster is a crucial issue. We aimed to evaluate the characteristics of physicians who left affected areas following the accident at Fukushima Daiichi Nuclear Power Plant caused by the Great East Japan Earthquake on March 11, 2011.…”
  3. 18863
  4. 18864
  5. 18865
  6. 18866
  7. 18867
  8. 18868
  9. 18869
  10. 18870

    Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE) by Ibrahima Gaye (8462562)

    Published 2025
    “…Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). …”
  11. 18871
  12. 18872
  13. 18873
  14. 18874

    Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) reverse methacholine airway hyperresponsiveness in rats by Mounira Tlili (12847046)

    Published 2022
    “…PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.…”
  15. 18875
  16. 18876

    Effect of mini-dose ready-to-use liquid glucagon on preventing exercise-associated hypoglycemia in adults with type 1 diabetes by Ronnie Aronson (3705877)

    Published 2023
    “…</p> <p>Research Design and Methods</p> <p>Individuals initially participated in the in-clinic training phase for which they were randomized to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. …”
  17. 18877

    Effects of PD-0332991 on BSG cell lines derived from genetically engineered mouse models. by Kelly L. Barton (465812)

    Published 2013
    “…<p>Cells were treated with PD-0332991 for 48 hours before being harvested for MTT or BrdU assays to assess cell survival and proliferation, respectively. (A) MTT assays (left panel) show minimal cytotoxic activity at doses up to 5µM in cell lines derived from PDGF-B; Ink4a-ARF deficient BSGs. …”
  18. 18878
  19. 18879
  20. 18880